ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder

cafead

Administrator
Staff member
  • cafead   Feb 11, 2022 at 11:52: AM
via ProQR Therapeutics N.V. shares are plunging after disappointing data from its pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated Leber congenital amaurosis 10 (LCA10).

article source
 

<